InvestorsHub Logo

5TOP

10/15/16 2:15 PM

#6686 RE: gestalt2 #6685

Could you post a source for this? I know Nader has purchased shares in the past but im pretty sure his last form 4 indicated that he doesnt currently own any shares. And I know he is committed to the science, but the remarks he made in the CC give me doubts to his commitment to shareholders and profitability. He seems to think that the results of PRO-140 will sell the company for him and that is simply not the case.

gestalt2

10/15/16 2:16 PM

#6687 RE: gestalt2 #6685

Also, I did send a long tough email to investor relations and talked with John on the phone about my concerns. His response is that due to the private offering and the increased # of shares that it takes more volume to support a stock. Also that the robotic selling that happened on thursday might just be a large position looking to scale out on any uptick to lower a cost basis, but he really does not know what any buying or selling motivations are. When i asked more directly about the reverse split and uplisting plan he really explained the problem. basically it is very difficult to get uplisted and that the cost per year is around $150k/year to be on the Nasdaq. it only costs about $15k on the OTC. Why waste the money when we know uplisting might lead to even more stock manipulation. additionally there is significant costs in reporting financials etc to be on the Nasdaq. I felt a lot better about things due mostly to the fact that it is obvious the company is focused on getting bought or a partnership, until that happens the stock price is not very important (dilution is however). He did also say that they are having no problem getting small to mid sized investment firms excited about cytodyn and that they own stock also.